ResMed Inc.
ResMed Declares $0.60 Quarterly Dividend and Reports Strong Q4 2025 Results
Summary
ResMed Inc. announced robust financial results for the fourth quarter and fiscal year 2025, reporting a 10% increase in revenue to $1.3 billion and a 19% increase in operating profit. The company also declared a quarterly cash dividend of $0.60 per share, payable on September 18, 2025, to holders of its common stock on the NYSE. ResMed's full-year revenue grew by 10% to $5.1 billion, and net income increased by 37% to $1.4 billion. The company's strong performance was driven by growth in its sleep devices and masks portfolio, as well as its expanding digital health ecosystem.
Profitelligence Alerts
Get alerts for RMD
Be first to know when ResMed Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Official SEC Documents
Advertisement